164 related articles for article (PubMed ID: 29120262)
1. Evaluation of Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution, 0.025% for Treatment of Ocular Redness.
Torkildsen GL; Sanfilippo CM; DeCory HH; Gomes PJ
Curr Eye Res; 2018 Jan; 43(1):43-51. PubMed ID: 29120262
[TBL] [Abstract][Full Text] [Related]
2. Low-dose brimonidine for relief of ocular redness: integrated analysis of four clinical trials.
Ackerman SL; Torkildsen GL; McLaurin E; Vittitow JL
Clin Exp Optom; 2019 Mar; 102(2):131-139. PubMed ID: 30525235
[TBL] [Abstract][Full Text] [Related]
3. Brimonidine Ophthalmic Solution 0.025% for Reduction of Ocular Redness: A Randomized Clinical Trial.
McLaurin E; Cavet ME; Gomes PJ; Ciolino JB
Optom Vis Sci; 2018 Mar; 95(3):264-271. PubMed ID: 29461408
[TBL] [Abstract][Full Text] [Related]
4. Brimonidine tartrate ophthalmic solution 0.025% for redness relief: an overview of safety and efficacy.
Lee JS; Kim CY
Expert Rev Clin Pharmacol; 2022 Aug; 15(8):911-919. PubMed ID: 35951740
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge.
Mah FS; Rosenwasser LJ; Townsend WD; Greiner JV; Bensch G
Curr Med Res Opin; 2007 Jun; 23(6):1445-52. PubMed ID: 17559743
[TBL] [Abstract][Full Text] [Related]
6. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.
Abelson MB; Torkildsen GL; Williams JI; Gow JA; Gomes PJ; McNamara TR;
Clin Ther; 2009 Sep; 31(9):1908-21. PubMed ID: 19843481
[TBL] [Abstract][Full Text] [Related]
7. OTC brimonidine (Lumify) for ocular redness.
Med Lett Drugs Ther; 2018 Oct; 60(1558):176. PubMed ID: 30335046
[No Abstract] [Full Text] [Related]
8. Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model.
Abelson MB; Greiner JV
Curr Med Res Opin; 2004 Dec; 20(12):1953-8. PubMed ID: 15701212
[TBL] [Abstract][Full Text] [Related]
9. Prolonged effectiveness of bepotastine besilate ophthalmic solution for the treatment of ocular symptoms of allergic conjunctivitis.
Williams JI; Kennedy KS; Gow JA; Torkildsen GL; Abelson MB; Gomes PJ; McNamara TR;
J Ocul Pharmacol Ther; 2011 Aug; 27(4):385-93. PubMed ID: 21649522
[TBL] [Abstract][Full Text] [Related]
10. Brimonidine gel 0.33% rapidly improves patient-reported outcomes by controlling facial erythema of rosacea: a randomized, double-blind, vehicle-controlled study.
Layton AM; Schaller M; Homey B; Hofmann MA; Bewley AP; Lehmann P; Nohlgård C; Sarwer DB; Kerrouche N; Ma YM
J Eur Acad Dermatol Venereol; 2015 Dec; 29(12):2405-10. PubMed ID: 26416154
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the comfort of Alphagan P compared with Alphagan in irritated eyes.
Mundorf T; Wilcox KA; Ousler GW; Welch D; Abelson MB
Adv Ther; 2003; 20(6):329-36. PubMed ID: 15058750
[TBL] [Abstract][Full Text] [Related]
12. Sedative and physiological effects of brimonidine tartrate ophthalmic solution in healthy cats.
Ogata N; Kanda T; Kawahata M; Ichikawa T; Matsumoto Y; Morimitsu W; Nishino Y; Itoi T; Furumoto K
Vet Anaesth Analg; 2017 Sep; 44(5):1091-1100. PubMed ID: 28865952
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies.
Fowler J; Jackson M; Moore A; Jarratt M; Jones T; Meadows K; Steinhoff M; Rudisill D; Leoni M
J Drugs Dermatol; 2013 Jun; 12(6):650-6. PubMed ID: 23839181
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of olopatadine ophthalmic solution 0.2% in reducing signs and symptoms of allergic conjunctivitis.
Abelson MB; Gomes PJ; Pasquine T; Edwards MR; Gross RD; Robertson SM
Allergy Asthma Proc; 2007; 28(4):427-33. PubMed ID: 17883910
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of comfort using olopatadine hydrochloride 0.1% ophthalmic solution in the treatment of allergic conjunctivitis in contact lens wearers compared to placebo using the conjunctival allergen-challenge model.
Brodsky M; Berger WE; Butrus S; Epstein AB; Irkec M
Eye Contact Lens; 2003 Apr; 29(2):113-6. PubMed ID: 12695716
[TBL] [Abstract][Full Text] [Related]
16. Improvement of objective ocular redness measured with Keratograph 5M in glaucoma patients after instilling brimonidine drops.
Montolío-Marzo E; Fernández-Narros R; Morales-Fernández L; García-Bella J; Sáenz-Francés F; García-Feijoo J; Martínez-de-la-Casa JM
Eur J Ophthalmol; 2024 Mar; 34(2):480-486. PubMed ID: 37661653
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the topical ocular antiallergic efficacy of emedastine 0.05% ophthalmic solution to ketorolac 0.5% ophthalmic solution in a clinical model of allergic conjunctivitis.
Discepola M; Deschenes J; Abelson M
Acta Ophthalmol Scand Suppl; 1999; (228):43-6. PubMed ID: 10337432
[TBL] [Abstract][Full Text] [Related]
18. A 3-month comparison of efficacy and safety of brimonidine-purite 0.15% and brimonidine 0.2% in patients with glaucoma or ocular hypertension.
Mundorf T; Williams R; Whitcup S; Felix C; Batoosingh A
J Ocul Pharmacol Ther; 2003 Feb; 19(1):37-44. PubMed ID: 12648302
[TBL] [Abstract][Full Text] [Related]
19. Multicenter, Randomized, Investigator-Masked Study Comparing Brimonidine Tartrate 0.1% and Timolol Maleate 0.5% as Adjunctive Therapies to Prostaglandin Analogues in Normal-Tension Glaucoma.
Mizoue S; Nitta K; Shirakashi M; Nitta A; Yamabayashi S; Kimura T; Ueda T; Takeda R; Matsumoto S; Yoshikawa K
Adv Ther; 2017 Jun; 34(6):1438-1448. PubMed ID: 28508306
[TBL] [Abstract][Full Text] [Related]
20. 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension.
Goñi FJ;
Eur J Ophthalmol; 2005; 15(5):581-90. PubMed ID: 16167288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
